SynthesisBMC neurology2025
Risk of colorectal cancer in Parkinson's disease: a systematic review and meta-analysis of 11 million participants.
Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk Between Parkinson's Disease and Colorectal Cancer: Genetic Mechanisms, Gut Microbiota, and Therapeutic Insights.Health care science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the last twenty years, epidemiological research has suggested a potential decreased susceptibility to cancer among individuals diagnosed with Parkinson's disease (PD), although conflicting findings exist regarding the connection between PD and Colorectal cancer (CRC). This systematic review and meta-analysis were conducted to investigate the contemporary epidemiological data on the risk of CRC in PD.
methodsA comprehensive search of the literature was conducted utilizing three databases: PubMed, Scopus, and Web of Science. We included observational studies (cross-sectional, case-control, and cohort) that examined the relationship between PD and CRC. We also analyzed data obtained from the Parkinson's Progression Markers Initiative (PPMI) to evaluate the frequency of CRC among individuals diagnosed with PD, control participants, and PD patients carrying the LRRK2 genetic variant.
resultsWe included 22 studies with a total of 1,3137,089 PD cases were included in our study. Our analysis demonstrated a significant relationship between PD and a reduced incidence of CRC (pooled RR = 0.80, 95% CI = 0.69-0.91). Subgroup analysis based on study design revealed a significant association in the cohort (pooled RR = 0.80, 95% CI = 0.66-0.93) and case-control studies (pooled RR = 0.77, 95% CI = 0.66-0.89). Also, sub-group analysis based on the study continent showed no significant association in North America (pooled RR = 0.83, 95% CI = 0.51-1.18, and Asia (pooled RR = 0.85, 95% CI = 0.55-1.15). However, analysis based on continents indicated significant results solely in Europe (pooled RR = 0.79, 95% CI = 0.71-0.86). PPMI analysis revealed distinct differences in CRC frequencies across the three groups (p < 0.001) with PD patients with LRRK2 genetic variant exhibited the highest frequency of colorectal cancer, followed closely by healthy subjects.
conclusionIn conclusion, our study demonstrates a decreased risk of CRC in individuals with PD, suggesting an inverse association between the two diseases. Further research is warranted to elucidate the underlying mechanisms driving this correlation, paving the way for the development of targeted strategies for the prevention and management of both PD and CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.